Skip to main content

Table 1 Summary of the demographic characteristics of the study groups

From: Which orally administered antithrombotic agent is most effective for preventing venous thromboembolism after total knee arthroplasty? A propensity score-matching analysis

  Total population (n = 799) Propensity-matched population (n = 351)
Aspirin (n = 168) Rivaroxaban (n = 117) Apixaban (n = 514) p value Aspirin (n = 117) Rivaroxaban (n = 117) Apixaban (n = 117) p value
Age (years) 68.7 ± 5.6 75.9 ± 6.0 71.1 ± 6.9 0.001 71.1 ± 4.5 75.9 ± 6.0 76.3 ± 5.9 <  0.001
     71.1 ± 4.5 75.9 ± 6.0   <  0.001
      75.9 ± 6.0 76.3 ± 5.9 0.644
Sex
 Male 19 (11.3) 22 (18.8) 42 (8.2) 0.003 18 (15.4) 22 (18.8) 20 (17.1) 0.786
 Female 149 (88.7) 95 (81.2) 472 (91.8) 99 (84.6) 95 (81.2) 97 (82.9)
Body mass index (kg/m2) 27.4 ± 3.8 26.4 ± 3.5 26.7 ± 3.4 0.021 27.1 ± 3.5 26.4 ± 3.5 26.2 ± 3.2 0.126
Type of surgery
 Unilateral 92 (54.8) 80 (68.4) 266 (51.8) 0.005 68 (58.1) 80 (68.4) 74 (63.2) 0.266
 Staged bilateral 76 (45.2) 37 (31.6) 248 (48.2) 49 (41.9) 37 (31.6) 43 (36.8)
Medial history
 HTN 103 (61.3) 81 (69.2) 333 (64.8) 0.387 78 (66.7) 81 (69.2) 83 (70.9) 0.777
 DM 32 (19.0) 26 (22.2) 111 (21.6) 0.746 26 (22.2) 26 (22.2) 30 (25.6) 0.775
 History of VTE 0 (0.0) 1 (0.9) 1 (0.2) a 0 (0.0) 1 (0.9) 1 (0.9) a
 History of CAD 12 (7.1) 7 (6.0) 19 (3.7) 0.151 10 (8.5) 7 (6.0) 7 (6.0) 0.669
 Heart valve disease 0 (0.0) 0 (0.0) 3 (0.6) a 0 (0.0) 0 (0.0) 2 (1.7) a
 Arrhythmia 3 (1.8) 6 (5.1) 11 (2.1) a 3 (2.6) 6 (5.1) 3 (2.6) a
 Malignant disease 13 (7.7) 9 (7.7) 33 (6.4) 0.785 9 (7.7) 9 (7.7) 10 (8.5) 0.962
  1. Values are presented as mean ± standard deviation or number (%). The statistical significance was set at p < 0.05
  2. HTN hypertension, DM diabetes mellitus, VTE venous thromboembolism, CAD coronary artery disease
  3. aThe frequency was too low to produce meaningful results